c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.
- Author:
Min-Xia SU
1
;
Yu-Lian XU
1
;
Xiao-Ming JIANG
1
;
Mu-Yang HUANG
1
;
Le-Le ZHANG
1
;
Luo-Wei YUAN
1
;
Xiao-Huang XU
1
;
Qi ZHU
1
;
Jian-Li GAO
2
;
Jia-Hong LU
1
;
Xiuping CHEN
1
;
Ming-Qing HUANG
3
;
Yitao WANG
1
;
Jin-Jian LU
1
Author Information
- Publication Type:Journal Article
- Keywords: Aggresomes; Everolimus; Ginsenoside Rh2; Lung cancer; P62; Paraptosis; TRIB3; c-MYC
- From: Acta Pharmaceutica Sinica B 2022;12(3):1240-1253
- CountryChina
- Language:English
- Abstract: The mammalian target of rapamycin (mTOR) pathway is abnormally activated in lung cancer. However, the anti-lung cancer effect of mTOR inhibitors as monotherapy is modest. Here, we identified that ginsenoside Rh2, an active component of Panax ginseng C. A. Mey., enhanced the anti-cancer effect of the mTOR inhibitor everolimus both in vitro and in vivo. Moreover, ginsenoside Rh2 alleviated the hepatic fat accumulation caused by everolimus in xenograft nude mice models. The combination of everolimus and ginsenoside Rh2 (labeled Eve-Rh2) induced caspase-independent cell death and cytoplasmic vacuolation in lung cancer cells, indicating that Eve-Rh2 prevented tumor progression by triggering paraptosis. Eve-Rh2 up-regulated the expression of c-MYC in cancer cells as well as tumor tissues. The increased c-MYC mediated the accumulation of tribbles homolog 3 (TRIB3)/P62+ aggresomes and consequently triggered paraptosis, bypassing the classical c-MYC/MAX pathway. Our study offers a potential effective and safe strategy for the treatment of lung cancer. Moreover, we have identified a new mechanism of TRIB3/P62+ aggresomes-triggered paraptosis and revealed a unique function of c-MYC.
